FIGURE 5.

Forest plot with the reported odds ratios (intention to treat) of improvement in liver fibrosis and MASH resolution in the 5 randomized controlled trials on GLP-1 receptor agonists for MASH. It is important to note that the study populations differ regarding fibrosis stage. All data from the randomization until last study-related procedure were included. Missing outcomes were reported as nonresponse. In the study by Newsome et al, only patients with primary outcome are included in the analysis. Study references (the severity of fibrosis), type of GLP-1 receptor agonist: Armstrong et al⁷⁶ (F0–F4): liraglutide; Newsome et al⁷⁷ (F1–F3), semaglutide, Loomba et al⁷⁸ (F4): semaglutide, Loomba et al⁴¹ (F2–F3): tirzepatide, Sanyal et al⁴² (F1–F3): survodutide. Abbreviations: GLP-1, glucagon-like peptide 1; MASH, metabolic dysfunction–associated steatohepatitis.